Drug intelligence / Profile preview

HY1839

Development stage: Unknown
Lead developer: Suzhou Pharmavan Cancer Research Center
Modality: Small Molecules
Administration: Oral

Overview

HY1839 is an investigational small molecule inhibitor developed by Suzhou Pharmavan Cancer Research Center for the treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. The drug functions as a selective inhibitor of Tyrosine Kinase 2 (TYK2), a member of the Janus kinase (JAK) family. By inhibiting TYK2, HY1839 modulates the signaling pathways of pro-inflammatory cytokines such as interleukin-12 (IL-12) and interleukin-23 (IL-23), which are key drivers of chronic inflammation in the gastrointestinal tract. HY1839 is currently in Phase 1 clinical development to assess its safety, tolerability, and pharmacokinetic profile in human subjects.

Targets

TYK2 (Tyrosine kinase 2)

Beyond the preview

Go deeper on HY1839.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HY1839.

Explore the full profile